Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar Lonial

Showing results (181-190 of 440) with videos related to

Pageof 44
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2020
DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 SignalingJie Li, Chaoyun Pan, Austin C Boese, et al.
Blood Cancer Journal|February 22, 2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experienceKathryn T Maples, Kevin H Hall, Nisha S Joseph, et al.
Research Square|April 1, 2024
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA VaccinationFrances Lee, Doan Nguyen, Ian Hentenaar, et al.
Blood|April 10, 2014
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cellsYanyan Gu, Jonathan L Kaufman, Leon Bernal, et al.
Transfusion|September 3, 2015
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trialNeera Jagirdar, R Donald Harvey, Ajay Nooka, et al.
Haematologica|May 5, 2022
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myelomaRemya Nair, Vimal Subramaniam, Benjamin G Barwick, et al.
Expert Opinion on Pharmacotherapy|November 14, 2018
Ixazomib for the treatment of multiple myelomaPaul G Richardson, Sonja Zweegman, Elizabeth K O'Donnell, et al.
Blood|December 2, 2006
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective studyAsher A Chanan-Khan, Jonathan L Kaufman, Jayesh Mehta, et al.
Scientific Reports|February 13, 2024
Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival cultureDoan C Nguyen, Celia Saney, Ian T Hentenaar, et al.
Blood|September 17, 2010
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomesEbenezer David, Jonathan L Kaufman, Christopher R Flowers, et al.
Pageof 44

Showing results (181-190 of 440) with videos related to

Sort By:
Pageof 44
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 29, 2020
DGKA Provides Platinum Resistance in Ovarian Cancer Through Activation of c-JUN-WEE1 SignalingJie Li, Chaoyun Pan, Austin C Boese, et al.
Blood Cancer Journal|February 22, 2023
Eliminating the monitoring period with subcutaneous daratumumab: a single-center experienceKathryn T Maples, Kevin H Hall, Nisha S Joseph, et al.
Research Square|April 1, 2024
The Majority of SARS-CoV-2 Plasma Cells are Excluded from the Bone Marrow Long-Lived Compartment 33 Months after mRNA VaccinationFrances Lee, Doan Nguyen, Ian Hentenaar, et al.
Blood|April 10, 2014
MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cellsYanyan Gu, Jonathan L Kaufman, Leon Bernal, et al.
Transfusion|September 3, 2015
Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trialNeera Jagirdar, R Donald Harvey, Ajay Nooka, et al.
Haematologica|May 5, 2022
β adrenergic signaling regulates hematopoietic stem and progenitor cell commitment and therapy sensitivity in multiple myelomaRemya Nair, Vimal Subramaniam, Benjamin G Barwick, et al.
Expert Opinion on Pharmacotherapy|November 14, 2018
Ixazomib for the treatment of multiple myelomaPaul G Richardson, Sonja Zweegman, Elizabeth K O'Donnell, et al.
Blood|December 2, 2006
Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective studyAsher A Chanan-Khan, Jonathan L Kaufman, Jayesh Mehta, et al.
Scientific Reports|February 13, 2024
Majority of human circulating IgG plasmablasts stop blasting in a cell-free pro-survival cultureDoan C Nguyen, Celia Saney, Ian T Hentenaar, et al.
Blood|September 17, 2010
Tipifarnib sensitizes cells to proteasome inhibition by blocking degradation of bortezomib-induced aggresomesEbenezer David, Jonathan L Kaufman, Christopher R Flowers, et al.
Pageof 44